Price target
Based on analysts projections #COGT is expected to experience a positive growth trajectory over the next year.
The current average COGT price target, as estimated by these analysts, is $20.33.
The predictions for the future COGT stock price range from a low of $15.00 to a high of $24.00, highlighting the variability of market expectations for COGT.
It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.
COGT stock forecasts by analyst
| Analyst / firm | Date | Rating | Price target | Price when posted |
|---|---|---|---|---|
| Needham | December 14, 2022 | Buy | 24.00 | 12.32 |
|
Chris Raymond Raymond James |
June 17, 2022 | Buy | 22.00 | 9.19 |
|
Christopher Liu Leerink Partners |
June 10, 2022 | Buy | 15.00 | 10.74 |
Cogent Biosciences (COGT) Fundamentals Checker
Financial metrics are used to evaluate financial stability which helps analysts determine if Cogent Biosciences is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.
Neutral
Financial Scores
Updated on: 06/12/2023
Altman Z-Score: 4.8
Piotroski Score: 2.0
ESG Score
Updated on: 06/12/2023
Environmental: 41.7
Social: 65.9
Governance: 70.9
Financial Health
Updated on: 06/12/2023
DCF: Strong Buy
ROE: Sell
ROA: Sell
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
COGT Discounted Cash Flow
Updated on: 06/12/2023
$14.143
Discounted Cash Flow Value
$8.630
Current Price
COGT Revenues by Segment
Updated on: 06/12/2023
Revenue from Contract with Customer, Excluding Assessed Tax
COGT Revenues by Region
Updated on: 06/12/2023
No available data
COGT Notes Due
Updated on: 06/12/2023
| CIK | Exchange | Title |
|---|
There are no data to display
9:00 AM (UTC)
Date:06 December, 2023
0
Twitter Sentiment
0.8724
Stocktwits Sentiment
Twitter Posts: 0 Twitter Comments: 0 Twitter Likes: 0 Twitter Impressions: 0
Stocktwits Posts: 1 Stocktwits Comments: 0 Stocktwits Likes: 0 Stocktwits Impressions: 4,331
1:00 AM (UTC)
Date:06 December, 2023
0
Twitter Sentiment
0
Stocktwits Sentiment
Twitter Posts: 0 Twitter Comments: 0 Twitter Likes: 0 Twitter Impressions: 0
Stocktwits Posts: 1 Stocktwits Comments: 0 Stocktwits Likes: 0 Stocktwits Impressions: 8,535
10:00 PM (UTC)
Date:05 December, 2023
0
Twitter Sentiment
0.6
Stocktwits Sentiment
Twitter Posts: 0 Twitter Comments: 0 Twitter Likes: 0 Twitter Impressions: 0
Stocktwits Posts: 1 Stocktwits Comments: 0 Stocktwits Likes: 0 Stocktwits Impressions: 8,531
1:00 PM (UTC)
Date:05 December, 2023
0
Twitter Sentiment
0.5
Stocktwits Sentiment
Twitter Posts: 0 Twitter Comments: 0 Twitter Likes: 0 Twitter Impressions: 0
Stocktwits Posts: 1 Stocktwits Comments: 0 Stocktwits Likes: 0 Stocktwits Impressions: 11,139
8:00 AM (UTC)
Date:05 December, 2023
0
Twitter Sentiment
0.6402
Stocktwits Sentiment
Twitter Posts: 0 Twitter Comments: 0 Twitter Likes: 0 Twitter Impressions: 0
Stocktwits Posts: 1 Stocktwits Comments: 0 Stocktwits Likes: 0 Stocktwits Impressions: 4,315
2:00 PM (UTC)
Date:03 December, 2023
0
Twitter Sentiment
0.58
Stocktwits Sentiment
Twitter Posts: 0 Twitter Comments: 0 Twitter Likes: 0 Twitter Impressions: 0
Stocktwits Posts: 1 Stocktwits Comments: 0 Stocktwits Likes: 0 Stocktwits Impressions: 13,651
Analyzing COGT Stock Forecast: Cogent Biosciences' Precision Therapy for Rare Genetic Diseases
Cogent Biosciences, whose stock ticker is COGT, is a biotechnology company that focuses on developing precision therapies for patients. Their research and development programs focus on the treatment of genetic diseases such as X-linked Hypophosphatemia (XLH), Genetic Epilepsies, and Charcot-Marie-Tooth (CMT) disease. Cogent Biosciences has already made significant strides in the field of genetic diseases. The company's lead candidate, CGT9486,... Read more
Cogent Biosciences Stock Prediction: Analyzing the Potential for High Returns in the Biotech Sector
The biotechnology sector is one of the most exciting and dynamic markets in the investment world. Biotech companies are focused on developing groundbreaking treatments for various diseases, ranging from cancer to genetic disorders. As such, investors often look to this sector for high potential returns. One company worth examining when analyzing the biotechnology stock market is Cogent Biosciences (ticker: COGT)....
However, when looking at predictions for Cogent Biosciences' stock performance both prior to and after it has released its trail data, there is always some inherent uncertainty involved with investments in early-stage biotech companies. Unlike more established firms like Pfizer or Merck with their extensive product lines and healthy revenue streams that can absorb setbacks along the way, small-cap stocks like COGT may experience far more pronounced swings based upon market uncertainty surrounding a potentially effective drug candidate.
Investing in biotech stocks requires patience and deep research. Investors need to remain up-to-date with key developments from companies such as Cogent Biosciences by closely following scientific publications regarding successes – or failures – related to their drug pipelines along with equity analyst insights who might provide additional context around such events.
In conclusion, while preclinical results look promising, Cogent Biosciences will need to present strong trial results or more compelling data on its work for stockholders to find enough of an argument to invest in this high-potential stock. Therefore, it could be appropriate for investors who are willing and comfortable with having a substantial amount of risk within their portfolio to explore the outcome of this clinical testing closer. As always, consulting a financial advisor beforehand can help individual investors better manage their asset allocations in deciding whether or not COGT represents an appealing opportunity within the biotech arena.">Read more
However, when looking at predictions for Cogent Biosciences' stock performance both prior to and after it has released its trail data, there is always some inherent uncertainty involved with investments in early-stage biotech companies. Unlike more established firms like Pfizer or Merck with their extensive product lines and healthy revenue streams that can absorb setbacks along the way, small-cap stocks like COGT may experience far more pronounced swings based upon market uncertainty surrounding a potentially effective drug candidate.
Investing in biotech stocks requires patience and deep research. Investors need to remain up-to-date with key developments from companies such as Cogent Biosciences by closely following scientific publications regarding successes – or failures – related to their drug pipelines along with equity analyst insights who might provide additional context around such events.
In conclusion, while preclinical results look promising, Cogent Biosciences will need to present strong trial results or more compelling data on its work for stockholders to find enough of an argument to invest in this high-potential stock. Therefore, it could be appropriate for investors who are willing and comfortable with having a substantial amount of risk within their portfolio to explore the outcome of this clinical testing closer. As always, consulting a financial advisor beforehand can help individual investors better manage their asset allocations in deciding whether or not COGT represents an appealing opportunity within the biotech arena.">Read more
Cogent Biosciences (COGT) Social Sentiments
Monitoring bullish and bearish sentiments towards Cogent Biosciences on Twitter and Stocktwits could help to forecast an upward or downward trend in Cogent Biosciences stock price.